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The Editorial on the Research Topic
Tumor Hypoxia: Impact in Tumorigenesis, Diagnosis, Prognosis, and Therapeutics
A key to advance the rational design of better tools for cancer detection, prognosis, and therapeu-
tics is to increase our knowledge of the tumor microenvironment. This concept is supported by 
a continuously growing volume of literature reviewed by Horsman and Vaupel. The stroma and 
tumor parenchyma coexist in a network of nutrients, growth factors, metabolites, acids, interstitial 
pressure, and other physiological agents (Elkhattouti et al.). The temporal and spatial dynamics of 
those complex interactions, considered “abnormal and adverse” relative to conditions of normal 
tissues (Horsman and Vaupel), affect individual cancer cells, contribute to the natural selection of 
distinct clones, and establish aggressive tumors.
Among the multiple components of the tumor microenvironment with strong effects on tumor 
aggressiveness, tumor-associated hypoxia is a particularly relevant one (Horsman and Vaupel). The 
abnormal and chaotic vasculature of growing solid tumors cannot provide proper delivery of oxygen 
to all tumor cells. Not only observed in solid tumors, but also in aggressive non-solid tumors as 
indicated by the Mazurier group (Deynoux et al.), irregular oxygen supply is a crucial component of 
tumorigenesis. A yet unexplored field related to the involvement of the hypoxia pathway in tumori-
genesis is its association with heritable cancer syndromes. Thus, the inactivating germline changes 
in tumor-suppressor genes belonging to DNA repair pathways are associated with an increased risk 
of carcinogenesis. Henegan and Gomez propose the hypoxia pathway can be linked to heritable 
cancer syndromes. Further exploration of this hypothesis may provide emergent concepts relevant 
for personalized stratification and treatment of tumors associated with germline mutations of genes 
associated with the hypoxia pathway.
Oxygen levels affect the cells largely by regulating activity of the transcription factor hypoxia-
inducible factor (HIF). Regulation of HIFα subunits is complex. As noted by Kietzmann et al., an 
array of kinases are key regulators of HIFα’s protein stability, subcellular localization, and transac-
tivatory properties. It is reasonable to propose that modulation of HIFα by phosphorylation may 
be cell type- and cellular context-dependent. This becomes relevant when kinases can be exploited 
as upstream therapeutic targets of HIFα subunits in cancer therapy. HIF is also controlled by other 
factors. Schober and Berra pinpoint deubiquitinating enzymes, known regulators of cellular protein 
stability, as counterbalancing factors of ubiquitin E3 ligases (Schober and Berra). Aberrant in cancer, 
the ubiquitination cycle of HIFα is associated with disease progression and poor prognosis (Schober 
and Berra).
Other intracellular signaling mechanisms such as stress or redox response mechanisms con-
stitute the hypoxia-activated gene expression program in tumors. For instance, the review from 
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Mazure  highlights the involvement of the voltage-dependent 
anion channel in cancer under the context of hypoxia. This chan-
nel, present in mitochondria, under hypoxia acts as a survival fac-
tor by promoting survival pathways in tumor cells and increased 
resistance to therapy agents (Mazure). These and other signaling 
molecules define a core for the response of cancer cells to varying 
oxygen conditions. Components of these networks adapt to low 
oxygen, play a critical role in tumor development, and offer a yet 
unexplored therapeutic potential.
Recently, tumor-associated hypoxia molecules have been 
identified as markers of poor prognosis. One example is carbonic 
anhydrase IX (CAIX), an enzyme involved in maintaining the 
cellular pH balance. Most of the studies, limited by low num-
bers of patients, were inconclusive. van Kuijk et al. provide the 
first comprehensive meta-analysis of the association between 
CAIX expression and treatment outcome in tumors. Patients 
having tumors with high CAIX expression have higher risk of 
locoregional failure and disease progression (van Kuijk et  al.). 
The results of this study suggest that measuring CAIX expression 
can improve disease management, which in turn may decrease 
overtreatment and clinical relapse.
Due to the adaptation mechanisms of cancer cells to low 
oxygen, hypoxic tumors have reduced sensitivity to cytotoxic 
therapeutic agents. Hepatoma upregulated protein (HURP), 
a hypoxia-related molecule (1), conferred radiation resistance 
to prostate cancer cells (2). Noted by Espinoza et  al. in their 
original research article, HURP expression in prostate tumors 
was associated with the increased expression of HIF-1α, vascular 
endothelial growth factor, and heat-shock protein 60, as well 
as increasing tumor grade. The data reinforce the relevance of 
hypoxia-related molecules as predictors of tumor aggressiveness, 
and propose a basis to further advance our understanding of the 
mechanistic role of hypoxia responsive molecules in therapy 
resistance.
On the establishment of novel approaches targeting hypoxia-
related targets, the Dedhar group proposes exploiting pH regula-
tion in the hypoxic niche (McDonald et al.). Since pH regulation 
is particularly relevant for cancer stem cells in hostile microen-
vironments, inhibition of pH regulatory enzymes, such as CAIX 
and monocarboxylate transporters, may result in a reduced 
response to hypoxia (McDonald et al.). Remarkably hypoxia pro-
motes various mechanisms of immunoevasion (McDonald et al.). 
A hypothesis that will need clinical validation can be proposed: 
use of checkpoint inhibitors to restore antitumor immunity in 
combination with inhibitors of pH regulation, in the context of 
hypoxia, may effectively target aggressive tumors.
Equally relevant for therapeutical development is the applica-
tion of novel models to study the adaptation of cancer cells to 
low oxygen. Chronic myeloid leukemia and hepatoblastoma 
are suggested by Cipolleschi et al. as tools to study low-oxygen-
sensitive, -resistant, and -adapted cancer stem cells. On the basis 
of new findings revealed by the use of these models, application 
of metabolic inhibitors to target cancer stem cells may have an 
unexplored therapeutic potential for treatment of highly refrac-
tory disease (Cipolleschi et al.).
On the success of any experimental drug targeting tumor 
hypoxia, the continued adaptability of tumors to their micro-
environmental stresses must be considered. Tumor cells are 
endowed with a very high plasticity and capacity to adapt. It is 
our challenge to find populations and conditions of the tumor 
microenvironment germane for target success. Interdisciplinary 
work will be the key for achievement of these goals. Benefits 
include; increased understanding of the involvement of hypoxia 
in tumorigenesis, development of better biomarker development, 
and more effective therapeutics.
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